Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 10 2023 - 08:47AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of May 2023
Commission File Number: 001-40299
Achilles Therapeutics plc
(Exact name of registrant as specified in its charter)
245 Hammersmith Road
London W6 8PW
United Kingdom
Tel: +44 (0)20 8154 4600
(Address, Including Zip Code, and Telephone Number, Including Area
Code, of Registrant’s Principal Executive Offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
☐
Achilles Therapeutics Reports First Quarter 2023 Financial Results
and Recent Business Highlights
On May 10, 2023, Achilles Therapeutics plc (“Achilles” or the
“Company”) issued a press release, a copy of which is furnished as
Exhibit 99.1 to this Current Report on Form 6-K, reporting its
financial results for the three month period ended March 31, 2023
and providing an update on recent business highlights. Furnished
(i) as Exhibit 99.2 to this Current Report on Form 6-K are the
Company’s unaudited consolidated financial statements for the three
month period ended March 31, 2023 and (ii) as Exhibit 99.3 to this
Current Report on Form 6-K is the Management’s Discussion and
Analysis of Financial Condition and Results of Operations for the
three month period ended March 31, 2023.
The statements contained in this “Achilles Therapeutics Reports
First Quarter 2023 Financial Results and Recent Business
Highlights” section of this Current Report on Form 6-K and the
information contained in Exhibits 99.1 and 99.2 shall not be deemed
“filed” for the purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), and is not
incorporated by reference into any of the Company’s filings under
the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date hereof, except as shall be
expressly set forth by specific reference in any such
filing.
INDEX TO EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly
authorized.
|
|
|
|
|
|
|
|
|
|
|
ACHILLES THERAPEUTICS PLC
|
|
|
|
|
Date: May 10, 2023
|
|
|
|
By:
|
|
/s/ Robert Coutts
|
|
|
|
|
|
|
Robert Coutts
|
|
|
|
|
|
|
Chief Financial Officer
|
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Aug 2023 to Sep 2023
Achilles Therapeutics (NASDAQ:ACHL)
Historical Stock Chart
From Sep 2022 to Sep 2023